BIO regulates the ex vivo expansion and function of hematopoietic stem cells by inhibiting GSK-3β
January 27-31, 2019
Hematopoietic stem cells (HSCs) have been applied in clinic settings for treating hematologic diseases, including leukemic disorders, immune deficiencies, and hemoglobinopathies. Umbilical cord blood(UCB) is an important source of HSCs. However, the low frequency of HSCs per unit of UCB remains a big hurdle to their wider applications. Wnt/β-catenin pathway plays important roles in the self-renewal of HSCs in vivo, but the roles of Wnt/β-catenin signaling on ex vivo expansion of HSCs remains controversial. GSK3β is the major regulator of Wnt pathway. Here, we evaluate the effects of 6-bromoindirubin-3’-oxime (BIO), a GSK3β inhibitor, on ex vivo expansion characteristics and regenerative potential of (UCB)-derived CD34+ cells.
Please click Additional Files below to see the full abstract.
Qihao Sun, Haibo Cai, and Wen-Song Tan, "BIO regulates the ex vivo expansion and function of hematopoietic stem cells by inhibiting GSK-3β" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). http://dc.engconfintl.org/cell_gene_therapies_vi/66